Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

被引：0

作者：

Janjigian, Yelena Y. ^{[1
]}

Al-Batran, Salah-Eddin ^{[2
]}

Wainberg, Zen A. ^{[3
]}

Van Cutsem, Eric ^{[4
,5
]}

Molena, Daniela ^{[6
]}

Muro, Kei ^{[7
]}

Hyung, Woo Jin ^{[8
]}

Wyrwicz, Lucjan ^{[9
]}

Oh, Do-Youn ^{[10
,11
]}

Omori, Takeshi ^{[12
]}

Moehler, Markus ^{[13
]}

Garrido, Marcelo ^{[14
,15
]}

Oliveira, Sulene C. S. ^{[16
]}

Liberman, Moishe ^{[17
]}

Oliden, Victor C. ^{[18
]}

Bilici, Mehmet ^{[19
]}

Kurland, John ^{[20
]}

Xynos, Ioannis ^{[20
]}

Mann, Helan ^{[20
]}

Tabernero, Josep ^{[21
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA

[2] Krankenhaus NW Frankfurt, Inst Clin Canc Res, Univ Canc Ctr, Frankfurt, Germany

[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA

[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium

[5] Katholieke Univ Leuven, Leuven, Belgium

[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea

[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea

[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan

[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany

[14] Clin Trial Ctr, London, England

[15] Univ Mayor, Santiago, Chile

[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Rio De Janeiro, Brazil

[17] Ctr Rech CHUM, Ctr Hosp Univ Montreal, Div Thorac Surg, Dept Surg, Montreal, PQ, Canada

[18] Natl Inst Neoplast Dis INEN & Detecta Clin, Lima, Peru

[19] Ataturk Univ, Fac Med, Dept Med Oncol, Erzurum, Turkiye

[20] AstraZeneca, Cambridge, England

[21] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Med Oncol Dept, IOB Quiron, Barcelona, Spain

来源：

ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S44 / S45

页数：2

共 50 条

[1] Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study
Janjigian, Yelena Y.
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan S.
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C. S.
Liberman, Moishe
Castro Oliden, Victor
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 245 - 246
[2] MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Marcovitz, Michelle
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
FUTURE ONCOLOGY, 2022, 18 (20) : 2465 - 2473
[3] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, double-blind, placebo-controlled, phase 3 study
Janjigian, Yelena
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
[4] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer-A randomized, double-blind, placebo-controlled, phase 3 study.
Janjigian, Yelena Y.
Van Cutsem, Eric
Muro, Kei
Wainberg, Zev A.
Al-Batran, Salah-Eddin
Hyung, Woo Jin
Molena, Daniela
Evans, Brent
Ruscica, Dario
Robbins, Scott H.
Negro, Alejandra
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Al-Batran, S.
Hyung, W.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S.
Negro, A.
Tabernero, J.
ANNALS OF ONCOLOGY, 2021, 32 : S118 - S118
[6] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, doubleblind, placebo-controlled, phase 3 study
Al-Batran, S. -E
Janjigian, Y.
Van Cutsem, E.
Muro, K.
Wainberg, Z.
Hyung, W. J.
Molena, D.
Evans, B.
Ruscica, D.
Robbins, S. H.
Negro, A.
Tabernero, J.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 218 - 218
[7] PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB PLUS 5FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND DOCETAXEL (FLOT) IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC): INTERIM RESULTS OF THE GLOBAL, PHASE 3 MATTERHORN STUDY
Molena, Daniela
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev A.
Van Cutsem, Eric
Muro, Kei
Hyung, Woo J.
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Moehler, Markus
Garrido, Marcelo
Oliveira, Sulene C.
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
GASTROENTEROLOGY, 2024, 166 (05) : S996 - S996
[8] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Moehler, Markus
Janjigian, Yelena
Al-Batran, Salah-Eddin
Wainberg, Zev
Van Cutsem, Eric
Molena, Daniela
Muro, Kei
Hyung, Woo Jin
Wyrwicz, Lucjan
Oh, Do-Youn
Omori, Takeshi
Garrido, Marcelo
Sousa, Oliveira Sulene Cunha
Liberman, Moishe
Oliden, Victor Castro
Bilici, Mehmet
Kurland, John F.
Xynos, Ioannis
Mann, Helen
Tabernero, Josep
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 229 - 229
[9] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Janjigian, Y. Y.
Al-Batran, S-E.
Wainberg, Z. A.
Van Cutsem, E.
Molena, D.
Muro, K.
Hyung, W. J.
Wyrwicz, L. S.
Oh, D. Y.
Omori, T.
Moehler, M.
Garrido, M.
Oliveira, S. Cunha Sousa
Liberman, M.
Oliden, V. Castro
Bilici, M.
Kurland, J. F.
Xynos, I.
Mann, H.
Tabernero, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1315 - S1316
[10] Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Oh, D-Y.
Janjigian, Y. Y.
Al-Batran, S-E.
Wainberg, Z. A.
van Cutsem, E.
Molena, D.
Muro, K.
Hyung, W. J.
Wyrwicz, L. S.
Omori, T.
Moehler, M.
Garrido, M.
Cunha Sousa Oliveira, S.
Liberman, M.
Castro Oliden, V.
Bilici, M.
Kurland, J.
Xynos, I.
Mann, H.
Tabernero, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1520 - S1521

← 1 2 3 4 5 →